SCHEMBL941149

SCHEMBL941149

CCOC(=O)c1c(N)nn2cccnc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.46
JAK3 P52333 1/20 0.46
TSHR P16473 4/20 0.46
PDE2A O00408 1/20 0.46
HSD17B10 Q99714 5/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
HTT P42858 1/20 0.45
ALDH1A1 P00352 5/20 0.44
HPGD P15428 5/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KDM4E B2RXH2 3/20 0.44
LMNA P02545 2/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.41
TP53 P04637 1/20 0.40
RAB9A P51151 1/20 0.40
PDE4D Q08499 1/20 0.40
PIK3CD O00329 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18675323 0.86 PDE2A (0.53) PDE2AHSD17B10ALDH1A1HPGDSMN1; SMN2
SCHEMBL3703081 0.85 PIK3CG (0.47) JAK2JAK3PDE2AHPGDLMNA
SCHEMBL23013712 0.84 HPGD (0.44) JAK2JAK3PDE2AHSD17B10ALDH1A1
SCHEMBL23728612 0.84 HPGD (0.44) PDE2AHSD17B10ALDH1A1HPGDSMN1; SMN2
SCHEMBL25422677 0.83 HPGD (0.46) PDE2AHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL31211903 0.82 ALDH1A1 (0.42) PDE2AHSD17B10ALDH1A1HPGDSMN1; SMN2
Acetic Acid SCHEMBL6126528 0.81 PIK3CG (0.47) JAK2JAK3PDE2AHPGDPIK3CD
SCHEMBL29525639 0.81 ALDH1A1 (0.41) JAK2JAK3TSHRPDE2AHSD17B10
SCHEMBL21585146 0.80 PIK3CG (0.44) JAK2JAK3PDE2APIK3CDPIK3CG
SCHEMBL23013190 0.80 EGFR (0.54) TSHRHSD17B10L3MBTL1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12447151-B2 Alkyne derivative, preparation method for same, and uses thereof HIS PHARMACEUTICAL CO., LTD. (CN) 2025-10-21 US disclosed
CN-115873000-B Isoquinolinones and quinazolinones compounds, and composition and application thereof 中山医诺维申新药研发有限公司 2025-02-28 CN disclosed
CN-113354653-B Diaryl macrocyclic polymorphs and processes for their preparation 特普医药公司 2024-12-31 CN disclosed
US-20240150364-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2024-05-09 US disclosed
US-20240109899-A1 BENZOFURAN COMPOUNDS AS STING AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-04 US disclosed
US-11939333-B2 Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same INFINITY PHARMACEUTICALS, INC. (US) 2024-03-26 US disclosed
US-11939333-B2 Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same INFINITY PHARMACEUTICALS, INC. (US) 2024-03-26 US disclosed
CN-114072409-B Alkyne derivative and preparation method and application thereof 浙江海正药业股份有限公司 2023-07-28 CN disclosed
WO-2023096850-A1 PHOSPHOINOSITIDE 3 KINASE GAMMA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF GEODE THERAPEUTICS INC. (US) 2023-06-01 WO disclosed
WO-2023096850-A1 PHOSPHOINOSITIDE 3 KINASE GAMMA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF GEODE THERAPEUTICS INC. (US) 2023-06-01 WO disclosed
WO-2015073267-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2015-05-21 WO disclosed
US-8999998-B2 Pyrazolopyrimidine JAK inhibitor compounds and methods GENENTECH, INC. (US) 2015-04-07 US disclosed
US-8999998-B2 Pyrazolopyrimidine JAK inhibitor compounds and methods GENENTECH, INC. (US) 2015-04-07 US disclosed
US-8999998-B2 Pyrazolopyrimidine JAK inhibitor compounds and methods GENENTECH, INC. (US) 2015-04-07 US disclosed
US-20120190665-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2012-07-26 US disclosed
US-20120190665-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2012-07-26 US disclosed
US-20120190665-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2012-07-26 US disclosed
EP-2448941-A2 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS Genentech, Inc. (US) 2012-05-09 EP disclosed
WO-2011003065-A2 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2011-01-06 WO disclosed
WO-2011003065-A2 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2011-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190665-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK1, JAK2, JAK3 JAK2 2/4885JAK3 3/4885TSHR 932/4885
US-20240150364-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK1, JAK2, JAK3 JAK2 2/4885JAK3 3/4885TSHR 932/4885
US-20240109899-A1 BENZOFURAN COMPOUNDS AS STING AGONISTS STING1, MAVS, IRF3 JAK2 1172/4885JAK3 2258/4885TSHR 4008/4885
US-11939333-B2 Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same PIK3CA, PIK3C2A, PIK3CD JAK2 126/4885JAK3 166/4885TSHR 4794/4885
US-12447151-B2 Alkyne derivative, preparation method for same, and uses thereof PIK3CD, PIK3R5, PIK3CA JAK2 19/4885JAK3 20/4885TSHR 2979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.